Patient Perspectives in Squamous Cell Carcinoma Clinical Trials
June 23, 2023 updated by: Power Life Sciences Inc.
An In Depth Study Examining Patterns in the Clinical Trial Experiences of Squamous Cell Carcinoma Patients
Clinical research participation has historically been heavily biased toward specific demographics.
This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma.
People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael B Gill
- Phone Number: (415) 900-4227
- Email: bask@withpower.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Power Life Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with squamous cell carcinoma who are actively considering enrolling in a clinical trial for said condition, but have not yet completed enrollment and randomization phases.
Description
Inclusion Criteria:
- Aged ≥ 18 years old
- Confirmed diagnosis of squamous cell carcinoma
- Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.
Exclusion Criteria:
- Inability to provide written informed consent
- Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
- Enrolled in another research study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients who decide to enroll in a squamous cell carcinoma clinical trial
Time Frame: 3 months
|
3 months
|
|
Rate of patients who remain in squamous cell carcinoma clinical trial to trial completion
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Leis M, Singh A, Li C, Ahluwalia R, Fleming P, Lynde CW. Risk of Vulvar Squamous Cell Carcinoma in Lichen Sclerosus and Lichen Planus: A Systematic Review. J Obstet Gynaecol Can. 2022 Feb;44(2):182-192. doi: 10.1016/j.jogc.2021.09.023. Epub 2021 Oct 19.
- Gupta S, Kamboj M, Narwal A. Knowing the unknown in oral squamous cell carcinoma: An observational study. J Cancer Res Ther. 2020 Apr-Jun;16(3):494-499. doi: 10.4103/jcrt.JCRT_898_18.
- Schlessinger DI, Iyengar S, Yanes AF, Chiren SG, Godinez-Puig V, Chen BR, Kurta AO, Schmitt J, Deckert S, Furlan KC, Poon E, Cartee TV, Maher IA, Alam M, Sobanko JF. Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. 2017 Jul 12;18(1):321. doi: 10.1186/s13063-017-2069-2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
June 23, 2023
First Submitted That Met QC Criteria
June 23, 2023
First Posted (Actual)
July 3, 2023
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 23, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 80490767
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.